SEC Tracker
Get the app

Estrella Immunopharma ESLA

Estrella Immunopharma Q1 FY26: net loss $2.3M; diluted EPS −$0.05

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Estrella Immunopharma reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$2.3MAgainst −$2.1M in Q1 FY2510-Q income statement, on EDGAR
  2. Diluted EPS−$0.05Against −$0.06 in Q1 FY2510-Q income statement, on EDGAR
  3. Total deposits$1.5MFlat against $1.5M in Q1 FY2510-Q balance sheet, on EDGAR
  4. Stockholders’ equity−$5.3MAgainst −$1.8M in Q1 FY2510-Q balance sheet, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Estrella Immunopharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Aligos Therapeutics ALGS public float $20M, Jun 30, 2025
  2. Armata Pharmaceuticals ARMP public float $21M, Jun 30, 2025
  3. CEL-SCI CVM public float $19M, Mar 31, 2025, over 18 months old
  4. Aptose Biosciences APTOF public float $22M, Jun 28, 2025
  5. BioAtla BCAB public float $19M, Jun 30, 2025